Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09. Oktober 2024 07:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
09. Oktober 2024 02:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
26. Juni 2024 04:00 ET
|
Spherix Global Insights
EXTON, PA, June 26, 2024 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis....
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
15. Mai 2024 08:35 ET
|
ZyVersa Therapeutics
ZyVersa is on track to achieve key development milestones over the next 3 quarters.
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
04. Januar 2024 07:50 ET
|
ZyVersa Therapeutics
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that...
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
01. März 2023 09:20 ET
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
27. Februar 2023 09:20 ET
|
ZyVersa Therapeutics
CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 which...
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
14. September 2022 09:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address...
Peripheral Intravenous Catheters Market To Reach USD 7.52 Billion By 2027 | Reports and Data
04. März 2020 12:00 ET
|
Reports and Data
New York, March 04, 2020 (GLOBE NEWSWIRE) -- The global Peripheral Intravenous Catheters market is forecast to reach USD 7.52 Billion by 2027, according to a new report by Reports and Data....
Nephros Announces $2.9 Million Private Placement
11. April 2018 07:30 ET
|
Nephros, Inc.
SOUTH ORANGE, NJ, April 11, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters...